Log in

NASDAQ:ALBO - Albireo Pharma Stock Price, Forecast & News

$24.74
+0.05 (+0.20 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$24.60
Now: $24.74
$25.13
50-Day Range
$21.81
MA: $24.49
$27.20
52-Week Range
$16.13
Now: $24.74
$38.69
Volume74,182 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:ALBO
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees39
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter.


Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

How were Albireo Pharma's earnings last quarter?

Albireo Pharma Inc (NASDAQ:ALBO) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.55) by $0.18. The biopharmaceutical company had revenue of $1.39 million for the quarter, compared to analyst estimates of $1.38 million. View Albireo Pharma's Earnings History.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Albireo Pharma.

What price target have analysts set for ALBO?

4 analysts have issued 1-year price objectives for Albireo Pharma's stock. Their forecasts range from $39.00 to $69.00. On average, they anticipate Albireo Pharma's stock price to reach $56.67 in the next year. This suggests a possible upside of 129.0% from the stock's current price. View Analyst Price Targets for Albireo Pharma.

What is the consensus analysts' recommendation for Albireo Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.

Has Albireo Pharma been receiving favorable news coverage?

News coverage about ALBO stock has trended extremely negative recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Albireo Pharma earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Albireo Pharma.

Are investors shorting Albireo Pharma?

Albireo Pharma saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 688,900 shares, a decrease of 13.0% from the January 15th total of 791,600 shares. Based on an average daily trading volume, of 77,500 shares, the short-interest ratio is currently 8.9 days. Currently, 6.8% of the shares of the company are short sold. View Albireo Pharma's Current Options Chain.

What other stocks do shareholders of Albireo Pharma own?

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the folowing people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 56)
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 67)
  • Dr. Paresh N. Soni, Consultant (Age 59)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Mr. Simon Harford, CFO & Treasurer

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (6.83%), Point72 Asset Management L.P. (1.67%), State Street Corp (1.53%), Chicago Capital LLC (1.38%), Victory Capital Management Inc. (1.20%) and Victory Capital Management Inc. (1.20%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford. View Institutional Ownership Trends for Albireo Pharma.

Which institutional investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Heartland Advisors Inc., Victory Capital Management Inc., Victory Capital Management Inc., Goldman Sachs Group Inc., Blair William & Co. IL, State Street Corp and Bank of America Corp DE. Company insiders that have sold Albireo Pharma company stock in the last year include Patrick Taylor Horn and Simon NR Harford. View Insider Buying and Selling for Albireo Pharma.

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was acquired by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Point72 Asset Management L.P., Bank of Montreal Can, California Public Employees Retirement System, MAI Capital Management, Alpine Global Management LLC, Birchview Capital LP and M&T Bank Corp. Company insiders that have bought Albireo Pharma stock in the last two years include Perceptive Advisors Llc and Ronald Harold Wilfred Cooper. View Insider Buying and Selling for Albireo Pharma.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $24.74.


MarketBeat Community Rating for Albireo Pharma (NASDAQ ALBO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  247 (Vote Outperform)
Underperform Votes:  272 (Vote Underperform)
Total Votes:  519
MarketBeat's community ratings are surveys of what our community members think about Albireo Pharma and other stocks. Vote "Outperform" if you believe ALBO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALBO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel